Literature DB >> 7664487

Antigen-specific B cells present cartilage proteoglycan (aggrecan) to an autoreactive T cell hybridoma derived from a mouse with proteoglycan-induced arthritis.

F R Brennan1, K Mikecz, E I Buzás, D Ragasa, G Cs-Szabó, G Negroiu, T T Glant.   

Abstract

Cartilage proteoglycan (aggrecan)-induced polyarthritis in BALB/c mice is characterized by chronic inflammation and destruction of joint tissues similar to that observed in human rheumatoid arthritis. The immunization of mice with fetal human proteoglycan (PG) elicits specific antibodies to the immunizing antigen of which a population cross-reacts with native mouse PG. This (auto)antibody production is immediately followed by an explosive proliferation of autoreactive T cells, suggesting that PG-specific B cells may participate in antigen presentation of PG to autoreactive T cells. We therefore isolated B cells from the spleens and lymph nodes of PG-immunized mice and examined their ability to present PG to a PG-specific T cell hybridoma. The antigen-specific T cell responses elicited by B cells from PG-immunized mice (both arthritic and clinically asymptomatic) were markedly higher than those of non-immune mice and keyhole limpet haemocyanin (KLH)-immunized mice, and these B cells could present low PG concentrations. Levels of B cell presentation corresponded with the serum levels of PG-specific antibodies, implying that these B cells were presenting the PG specifically via their surface immunoglobulin. This B cell-T cell interaction was strongly dependent on MHC class II/T cell receptor (TCR), LFA-1/intercellular adhesion molecule-1 (ICAM-1) and CD28/B7 interactions, as antibodies to Ia, ICAM-1 and B7-2 (but not to B7-1) markedly reduced presentation. These data indicate that PG-specific B cells may play an essential role in governing the development of PG-induced arthritis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7664487      PMCID: PMC1553246          DOI: 10.1111/j.1365-2249.1995.tb03128.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  T and B cell connections in experimentally induced autoimmunity.

Authors:  D K Male; G Pryce; A Cooke; P Hutchings; S Marshall-Clarke; I M Roitt
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

2.  B220: a B cell-specific member of th T200 glycoprotein family.

Authors:  R L Coffman; I L Weissman
Journal:  Nature       Date:  1981-02-19       Impact factor: 49.962

3.  Evidence that a humoral immune response to autologous cartilage proteoglycan can participate in the induction of cartilage pathology.

Authors:  T F Kresina; J U Yoo; V M Goldberg
Journal:  Arthritis Rheum       Date:  1988-02

4.  Immunity to cartilage proteoglycans in BALB/c mice with progressive polyarthritis and ankylosing spondylitis induced by injection of human cartilage proteoglycan.

Authors:  K Mikecz; T T Glant; A R Poole
Journal:  Arthritis Rheum       Date:  1987-03

5.  Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint.

Authors:  E R Pettipher; G A Higgs; B Henderson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

6.  Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones.

Authors:  M K Jenkins; D M Pardoll; J Mizuguchi; T M Chused; R H Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

7.  Mechanisms of T and B cell collaboration in the in vitro production of anti-DNA antibodies in the NZB/NZW F1 murine SLE model.

Authors:  D G Ando; E E Sercarz; B H Hahn
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

8.  Proteoglycan-induced arthritis in BALB/c mice. Clinical features and histopathology.

Authors:  T T Glant; K Mikecz; A Arzoumanian; A R Poole
Journal:  Arthritis Rheum       Date:  1987-02

9.  Age-related changes in protein-related epitopes of human articular-cartilage proteoglycans.

Authors:  T T Glant; K Mikecz; P J Roughley; E Buzás; A R Poole
Journal:  Biochem J       Date:  1986-05-15       Impact factor: 3.857

10.  Antigen presentation by resting B cells. Radiosensitivity of the antigen-presentation function and two distinct pathways of T cell activation.

Authors:  J D Ashwell; A L DeFranco; W E Paul; R H Schwartz
Journal:  J Exp Med       Date:  1984-03-01       Impact factor: 14.307

View more
  6 in total

1.  Presentation of the candidate rheumatoid arthritis autoantigen aggrecan by antigen-specific B cells induces enhanced CD4(+) T helper type 1 subset differentiation.

Authors:  Caroline L Wilson; Dominic W Hine; Ariel Pradipta; Jeffrey P Pearson; Willem van Eden; John H Robinson; Andrew M Knight
Journal:  Immunology       Date:  2012-04       Impact factor: 7.397

Review 2.  B-cell involvement in the pathogenesis of RA-is there a contribution of the sympathetic nervous system?

Authors:  Georg Pongratz; Rainer H Straub
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  B cells are important as antigen presenting cells for induction of MHC-restricted arthritis in transgenic mice.

Authors:  Veena Taneja; Christopher J Krco; Marshall D Behrens; Harvinder S Luthra; Marie M Griffiths; Chella S David
Journal:  Mol Immunol       Date:  2007-02-14       Impact factor: 4.407

4.  Complex pattern of Th1 and Th2 activation with a preferential increase of autoreactive Th1 cells in BALB/c mice with proteoglycan (aggrecan)-induced arthritis.

Authors:  K Holló; T T Glant; M Garzó; A Finnegan; K Mikecz; E Buzás
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

5.  Aggrecan: A Target Molecule of Autoimmune Reactions.

Authors:  Edit I Buzás; Katalin Mikecz; Tibor T Glant
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

Review 6.  Tissue-associated autoantigens in rheumatoid arthritis. Tissue-antigens detected by autoantibodies in synovial fluid and sera of RA patients.

Authors:  P von Landenberg; J Schölmerich
Journal:  Clin Rev Allergy Immunol       Date:  2000-02       Impact factor: 10.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.